{"id":"W4250306919","doi":"10.1200/jco.2013.31.4_suppl.lba445","title":"Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; FOLFOX; FOLFIRI; Internal medicine; Neutropenia; Bevacizumab; Clinical endpoint; Placebo; Colorectal cancer; Pegfilgrastim; Febrile neutropenia; Gastroenterology; Regimen; Surgery; Oncology; Randomized controlled trial; Chemotherapy; Irinotecan; Oxaliplatin; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004478093,0.0002313385,0.004969615,0.000332369,0.00005580992,0.000010938,0.0001571521,0.000451725,0.000237917],"category_scores_gemma":[0.01073361,0.000143511,0.000952311,0.0002453876,0.0003535192,0.0001823718,0.00005462888,0.0007124313,0.000001373064],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001925015,"about_ca_system_score_gemma":0.001791556,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004745934,"about_ca_topic_score_gemma":0.001506103,"domain_scores_codex":[0.9925312,0.0005174109,0.005960058,0.0002874582,0.0003982354,0.0003056525],"domain_scores_gemma":[0.9824945,0.01095601,0.004716789,0.0001751452,0.001339017,0.0003185174],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9531503,0.006469805,0.001793431,0.00007621145,0.001054191,0.00001652386,0.0001865533,0.00007510091,0.00008302433,0.0000115729,0.001794859,0.03528843],"study_design_scores_gemma":[0.9394221,0.05490438,0.001236289,0.0003130421,0.001583604,0.00002821419,0.00004810247,0.0005805691,0.000188139,0.0001331019,0.001441321,0.0001211745],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9862385,0.0001579441,0.0001440548,0.002979047,0.001912339,0.007929326,0.00003151206,0.000006212527,0.0006010156],"genre_scores_gemma":[0.9959194,0.001140639,0.0007074745,0.0001853512,0.0009814843,0.0007445791,0.000007960385,0.00002373808,0.000289386],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04843457,"threshold_uncertainty_score":0.9975994,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1036474043815489,"score_gpt":0.4599664402436699,"score_spread":0.356319035862121,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}